Novartis India

Ex-date alert! These 16 stocks go ex-dividend on July 22; are you eligible?

Here is the complete list of stocks that will trade ex-dividend on July 23, following their announcements of dividend rewards for shareholders

Novartis soars 11%; board to support parent firm explore strategic options

According to reports, Dr Reddy's Laboratories is likely in a race to acquire Novartis AG's stake in Novartis India.

Novartis announces strategic review of Novartis India Limited

Drug major Novartis AG on Friday announced a strategic review of Novartis India Ltd, a public company listed on the BSE. The strategic review will include an assessment of the 70.68 per cent shareholding of Novartis AG in the company, the drug firm said in a statement. Novartis India Ltd is separate from Novartis Healthcare Pvt Ltd, the wholly owned subsidiary of Novartis group in India. Novartis Healthcare Pvt Ltd includes the Novartis Corporate Centre in Hyderabad, the commercial arm of Novartis in India, and R&D teams, which currently conduct clinical trials at more than 300 trial sites in the country. The strategic review will not impact Novartis Healthcare Pvt Ltd, Novartis AG stated. There can be no assurance that the strategic review of Novartis India Ltd will be completed in 2024, or that the outcome would result in the implementation of any transaction, it said. Novartis remains deeply committed to India with a footprint that has expanded significantly in recent years, i

JB Pharma, Novartis ink Rs 1,089 cr deal for select ophthalmology brands

JB Chemicals & Pharmaceuticals Ltd (JB Pharma)on Tuesday said it has inked a trade mark licence agreement along with promotion and distribution pact with Novartis for select ophthalmology brands entailing a total sum of Rs 1,089 crore. The board of directors at its meeting held on December 19, 2023 approved the execution of a trade mark licence agreement with Novartis Innovative Therapies AG, which is perpetual in nature for the Indian market, for a portfolio of select ophthalmology brands which will be effective in January 2027, JB Pharma said in a regulatory filing. The board also approved the promotion and distribution agreement with Novartis Healthcare Pvt Ltd for the same portfolio of select ophthalmology brands for the Indian market for a period of three years starting December 2023, it added. On the financial details of the agreements, JB Pharma said it will pay USD 116 million (Rs 964 crore), excluding applicable taxes, stamp duty and working capital, for the trade marks ..

Drug firm Novartis reports 29% increase in net profit at Rs 23.68 cr

Drug firm Novartis India on Friday reported 29.04 per cent increase in net profit at Rs 23.68 crore for the second quarter ended September 30, 2023. The company had logged a net profit of Rs 18.35 crore in the year-ago period, according to a regulatory filing by Novartis India. However, revenue from operations was down 22.41 per cent at Rs 78.76 crore as against Rs 101.52 crore, it added. Total expense was at Rs 63.21 crore, down 27.4 per cent. Shares of Novartis India on Friday settled at Rs 684.50 apiece on BSE, up 6.06 per cent from the previous close.

Price war begins for Novartis cardiac drug as JB Pharma cuts rate by 50%

Novartis' blockbuster drug is set to lose patent in Jan; JB Pharma, one of the four marketers in India of generi versions, has slashed the price of its brand Azmarda to Rs 39.6 a tablet

Dr Reddy's Laboratories inks exclusive sales pact with Novartis India

Dr Reddy's Laboratories has entered into an exclusive sales and distribution agreement with Novartis India Ltd (NIL), a statement said

HDFC Bank, IndusInd in 'red flag' list on nearing foreign investment cap

A listed company enters the list when the available legroom for overseas investment is less than 3 per cent of the permissible limit

Novartis India Q1 net profit jumps over 5-fold to Rs 4.39 cr on price cuts

The company had posted a net profit of Rs 79 lakh in the corresponding period of previous fiscal

Top headlines: Govt to set up Rs 1-trn agri infra fund, job cuts at Zomato

Business Standard brings to you the top headlines of the day

Novartis India appoints Sanjay Murdeshwar as MD and vice chairman

Pharma firm Novartis India Saturday announced the appointment of Sanjay Murdeshwar as vice chairman and managing director of the company. "..based on recommendation of the Nomination and Remuneration Committee of the Board, the Board of Directors of Novartis lndia Ltd at their meeting held today, have approved the appointment of Sanjay Murdeshwar as Vice Chairman & Managing Director of the Company effective June 15, 2019, subject to the approval of Shareholders and Central Government," a company statement said. Murdeshwar is Country President, Novartis in India and responsible for the company's pharmaceuticals business in the country. He is also managing director of Novartis Healthcare Private Ltd. Murdeshwar comes with more than 20 years of experience in the healthcare industry which includes varied roles in the pharmaceuticals and consumer health businesses, it added.

Novartis India MD Milan Paleja to step down with effect from May 31

The company's board has requested the nomination and remuneration committee to identify and recommend a suitable successor for the role

Novartis India board clears share buyback worth Rs 231 cr

Shares of Novartis India were trading 6.85% down at Rs 635.85 apiece on BSE

Novartis India slips 8% as buyback price disappoints

The board approved share buyback at a price of Rs 670 per share, against Friday's close of Rs 683 on BSE.

Novartis India surges 7% as board mulls share buyback

So far in 2017, the stock under-performed the market by falling 24% as compared to 22% rise in the S&P BSE Sensex till Wednesday.

Novartis India Q1 net at Rs 19 crore

The company's shares were trading at Rs 718 per scrip on BSE, up 1.90%

Novartis India dips after board approves share buyback

The stock dipped 13% to Rs 720 after the board approved the buyback of shares at a price of Rs 760 through tender offer.

Novartis India surges on share buyback plans

The stock surged 15% to Rs 818 on the BSE in early morning trade.